Jump to navigation Jump to search

WikiDoc Resources for BL22


Most recent articles on BL22

Most cited articles on BL22

Review articles on BL22

Articles on BL22 in N Eng J Med, Lancet, BMJ


Powerpoint slides on BL22

Images of BL22

Photos of BL22

Podcasts & MP3s on BL22

Videos on BL22

Evidence Based Medicine

Cochrane Collaboration on BL22

Bandolier on BL22

TRIP on BL22

Clinical Trials

Ongoing Trials on BL22 at Clinical

Trial results on BL22

Clinical Trials on BL22 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on BL22

NICE Guidance on BL22


FDA on BL22

CDC on BL22


Books on BL22


BL22 in the news

Be alerted to news on BL22

News trends on BL22


Blogs on BL22


Definitions of BL22

Patient Resources / Community

Patient resources on BL22

Discussion groups on BL22

Patient Handouts on BL22

Directions to Hospitals Treating BL22

Risk calculators and risk factors for BL22

Healthcare Provider Resources

Symptoms of BL22

Causes & Risk Factors for BL22

Diagnostic studies for BL22

Treatment of BL22

Continuing Medical Education (CME)

CME Programs on BL22


BL22 en Espanol

BL22 en Francais


BL22 in the Marketplace

Patents on BL22

Experimental / Informatics

List of terms related to BL22

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

BL22, also called CAT-3888 or GCR-3888, is an immunotoxin which attaches to and, upon internalization, kills B cells. It has completed a Phase I clinical (human) trial and is currently in a Phase II clinical trial for the treatment of hairy cell leukemia at a Phase I clinical trial for pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma[2] at the NIH in the U.S. It may be useful against any B cell leukemia or lymphoma.

Technically, BL22 is an anti-CD22 immunotoxin fusion protein between a murine anti-CD22 disulphide-linked Fv (dsFv) antibody fragment and an edited copy of bacterial Pseudomonas exotoxin PE38. The toxin is activated intracellularly, by the low pH of the lysosome into which the entire protein was internalized via the CD22 receptor. The toxin kills the targeted cell through ribosome inactivation.[3]

BL22 is very similar to the newer HA22, which changes one amino acid in the antibody fragment to increase the binding affinity for the target molecule. Both of these proteins are designed to bind to the CD22 receptor on the surface of B cells.

Business History

BL22 was initially designed and produced at the U.S. National Cancer Institute, one of the agencies which make up the NIH. Early development of BL22 was funded by California biotech Genencor.[4] The future drug was acquired by Cambridge Antibody Technology at the end of 2005; less than a year later, CAT was purchased by British pharmaceutical company AstraZeneca.[5]

Template:WikiDoc Sources